ReVision Optics lands $32M funding to commercialize flagship product
November 14, 2016
ReVision Optics, a provider of corneal inlays to correct farsightedness, has secured a $32 million investment led by JJDC, the venture capital subsidiary of Johnson & Johnson (NYSE: JNJ); existing investors Canaan Partners, Domain Associates, InterWest Partners and ProQuest Investments also participated. The company has now raised about $165 million of equity funding, and proceeds from the most recent round will go toward expanding the commercialization of its flagship product, which completed its first commercial cases in August after securing regulatory approval in June.
Here’s a look at some of ReVision Optics’ financing and valuation history:
October 2005: $13M round | $25M valuation May 2007: $25M | $55M May 2010: $35M | $86M April 2013: $15M | $112M July 2013: $40M | $183M